1. Cell Cycle/DNA Damage
  2. PPAR


PPARs (Peroxisome proliferator-activated receptors) are ligand-activated transcription factors of nuclear hormone receptor superfamily comprising of the following three subtypes: PPARα, PPARγ, and PPARβ/δ. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. All PPARs heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the DNA of target genes. Activation of PPAR-α reduces triglyceride level and is involved in regulation of energy homeostasis. Activation of PPAR-γ causes insulin sensitization and enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism.

PPAR Related Products (56):

Cat. No. Product Name Effect Purity
  • HY-16578
    GW9662 Antagonist 99.53%
    GW9662 is a selective PPAR antagonist for PPARγ with IC50 of 3.3 nM, with ~10 and ~1000-fold functional selectivity in cells against PPARα and PPARδ, respectively.
  • HY-17386
    Rosiglitazone Agonist 99.46%
    Rosiglitazone is a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, and is a blocker of TRPM2 and TRPM3 channels.
  • HY-14649
    Retinoic acid Agonist 98.36%
    Retinoic acid is a natural agonist of RAR/RXR nuclear receptors.
  • HY-16737
    Elafibranor Agonist 99.31%
    Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α (PPAR-α) and peroxisome proliferator-activated receptor-δ (PPAR-δ) with EC50 values of 45 and 175 nM, respectively.
  • HY-50935
    Troglitazone Agonist
    Troglitazone is a PPARγ agonist with anti-inflammatory and anti-tumor activity.
  • HY-N0182
    Fisetin >98.0%
    Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
  • HY-104049
    Lanifibranor Agonist
    Lanifibranor is a pan peroxisome proliferator-activated receptor (PPAR) agonist.
  • HY-U00068
    PPARα-MO-1 Modulator
    PPARα-MO-1 is a potent PPARα modulator extracted from patent WO/2004/110982A1, formula I.
  • HY-10838
    GW 501516 Agonist 99.26%
    GW 501516 is a PPARδ agonist with an EC50 of 1.1 nM.
  • HY-14601
    Pioglitazone hydrochloride Agonist 99.53%
    Pioglitazone hydrochloride is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
  • HY-15725
    CDDO-Im Agonist 98.20%
    CDDO-Im (CDDO-imidazolide) is a synthetic triterpenoids with anti-cancer and anti-inflammatory activities.
  • HY-17356
    Fenofibrate Agonist 99.92%
    Fenofibrate is a relatively potent inhibitor of CYP2C19 (IC50=0.2 μM) and CYP2B6 (IC50=0.7 μM).
  • HY-13202
    T0070907 Antagonist 99.98%
    T0070907 is a potent PPARγ antagonist and a potential RAD51 inhibitor, with the IC50 value of 1 nM towards PPARγ.
  • HY-13928
    GW0742 Agonist 99.63%
    GW0742 (GW610742) is a potent and highly selective PPARδ agonist. EC50 values are 1nM, 1.1μM and 2 μM for transactivation of human PPARδ, -α, and -γ receptors respectively.
  • HY-N0019
    Daidzein Activator 99.69%
    Daidzein is a soy isoflavone, which acts as a PPAR activator.
  • HY-17618
    Pemafibrate Modulator 99.78%
    Pemafibrate is a novel selective PPARα modulator (SPPARMα) that has antihyperlipidaemic activity.
  • HY-16995
    Wy-14643 Agonist 99.69%
    Wy-14,643 (Pirinixic acid) is a moderate agonist of PPARα and PPARγ with IC50 of 36.5 μM and 53.7 μM, respectively.
  • HY-10678
    BMS-687453 Agonist 99.70%
    BMS-687453 is a potent and selective PPARα agonist, with an EC50 of 10 nM for human PPARα and 410-fold selectivity vs human PPARγ in PPAR-GAL4 transactivation assays.
  • HY-12377
    GSK0660 Antagonist 99.27%
    GSK0660 is a specific antagonist of PPARβ/δ, also has inverse agonist effects when used alone.
  • HY-N0796
    Procyanidin B2 Inhibitor 99.36%
    Procyanidin B2 exerts a potent and beneficial role in reducing granulosa cell apoptosis and inducing autophagy process,and exerts a variety of potent protective pharmacological effects on diabetic complications.